NovaBridge adds Martin Dewhurst to board, committees

NovaBridge Biosciences (NBP) appointed Martin Dewhurst as an independent director to its Board of Directors, effective September 8, 2026, and named him to both the Audit Committee and the Compensation Committee.

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) appointed Martin Dewhurst as an independent director to its Board of Directors, effective September 8, 2026, and named him to both the Audit Committee and the Compensation Committee. His background includes more than 30 years of board and C‑suite experience across biotech, biopharma, medical devices, health tech and healthcare investment.

The company highlights his prior leadership roles at McKinsey & Company, including co-leading the Global Life Sciences Practice and co-founding the McKinsey Health Institute, as well as multiple current board and advisory positions in global healthcare organizations. The appointment follows the departure of independent director Liu Xin. This report, excluding the press release exhibit, is incorporated by reference into NovaBridge’s existing Form F‑3 and multiple Form S‑8 registration statements.

Key Figures

Effective appointment date: September 8, 2026 Industry experience: Over 30 years Referenced Form F-3 file number: 333-286954

3 metrics

Effective appointment date September 8, 2026 Date Martin Dewhurst’s role as independent director and committee member became effective

Industry experience Over 30 years Martin Dewhurst’s experience across biotech, biopharma, medical devices, health tech and healthcare investment

Referenced Form F-3 file number 333-286954 Registration Statement on Form F-3 into which this 6-K (excluding Exhibit 99.1) is incorporated by reference

Key Terms

independent director, Audit Committee, Compensation Committee, Registration Statement on Form F-3, +2 more

6 terms

independent director regulatory

"appointed as an independent director of the Board of Directors"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Audit Committee regulatory

"member of each of the Audit Committee and the Compensation Committee"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

Compensation Committee regulatory

"member of each of the Audit Committee and the Compensation Committee"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Registration Statement on Form F-3 regulatory

"incorporated by reference into the Company’s Registration Statements on Form F-3"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

Form S-8 regulatory

"Registration Statements on Form F-3 and Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

forward-looking statements regulatory

"This announcement contains forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What board changes did NovaBridge Biosciences (NBP) announce on September 8, 2026?

NovaBridge Biosciences appointed Martin Dewhurst as an independent director to its Board of Directors and as a member of both the Audit Committee and the Compensation Committee, effective September 8, 2026. The appointment follows the departure of independent director Liu Xin.

What is Martin Dewhurst’s background relevant to NovaBridge Biosciences (NBP)?

Martin Dewhurst has over 30 years of experience across biotech, biopharma, medical devices, health tech, and healthcare investment. He spent more than three decades at McKinsey & Company, including co-leading the Global Life Sciences Practice and co-founding the McKinsey Health Institute.

Which board committees will Martin Dewhurst serve on at NovaBridge Biosciences (NBP)?

Martin Dewhurst will serve as a member of NovaBridge Biosciences’ Audit Committee and Compensation Committee. He joins the Board as an independent director, bringing governance and strategic advisory experience across multiple healthcare sectors.

How is this NovaBridge Biosciences (NBP) 6-K incorporated by reference?

The information in this Form 6-K, excluding Exhibit 99.1, is incorporated by reference into NovaBridge’s Form F-3 registration statement (File No. 333-286954) and its Form S-8 registration statements, becoming part of those filings as of the furnishing date.

Which other organizations does NovaBridge director Martin Dewhurst currently serve?

Martin Dewhurst serves on the boards of Swixx BioPharma AG, Turn Therapeutics Inc. (Nasdaq: TTRX), Unilabs SA, Cytovation ASA, and Distalmotion SA, and holds advisory roles with Revival Healthcare Capital, PJT Partners’ Life Sciences practice, and Lightrock.

What are NovaBridge Biosciences’ main therapeutic focus areas mentioned in this 6-K?

NovaBridge Biosciences is described as a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. Its portfolio is led by programs referred to as givastomig and VIS-101.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 07:00 AM Accepted by SEC EDGAR 09/08/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

Appointment of Independent Director

On September 8, 2026, NovaBridge Biosciences (the “Company”) announced the appointment of Martin Dewhurst as an independent director of the Board of Directors of the Company (the “Board”) and as a member of each of the Audit Committee and the Compensation Committee of the Board, effective September 8, 2026.

From 1992 to April 2023, Mr. Dewhurst was with McKinsey & Company, where he co-founded and co-led the McKinsey Health Institute from June 2021 to April 2023 and co-led the firm’s Global Life Sciences Practice from 2014 to 2021. Earlier in his career, Mr. Dewhurst served as an engagement manager at Arthur Andersen & Co. and as a marketing manager at BP Solar.

Mr. Dewhurst currently serves on the boards of directors of Swixx BioPharma AG, Turn Therapeutics Inc. (Nasdaq: TTRX), Unilabs, Cytovation ASA and Distalmotion SA. He also serves on the Remuneration Committee of Cytovation ASA and chairs the Audit Committee of Distalmotion SA. From April 2023 to January 2025, he served as Chair of the Advisory Board of MedGenome Labs Ltd. Mr. Dewhurst also holds advisory and external partner roles with healthcare and investment organizations, including Revival Healthcare Capital, Lightrock and PJT Partners.

Mr. Dewhurst holds a Master of Business Administration from INSEAD, and a Bachelor of Arts from Magdalen College, University of Oxford.

A copy of the press release announcing Mr. Dewhurst’s appointment is attached hereto as Exhibit 99.1.

Incorporation by Reference

The information set forth in this report on Form 6-K, excluding Exhibit 99.1, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684, File No. 333-279842, File No. 333-290195 and File No. 333-298369) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release – NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NovaBridge Biosciences
	By	:	/s/ Kyler Lei
	Name	:	Kyler Lei
	Title	:	Chief Financial Officer

Date: September 8, 2026

NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

•Martin Dewhurst appointed as independent director and member of the Audit and Compensation Committees

•Veteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience

ROCKVILLE, MD, September 8, 2026 (GLOBE NEWSWIRE) – NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced the appointment of Martin Dewhurst to its Board of Directors (the “Board”) as an independent director, and as a member of both the Audit Committee and the Compensation Committee, effective immediately.

Mr. Dewhurst is a global healthcare leader with more than 30 years of Board and C-suite experience across biotech, biopharma, medical devices, health tech, and healthcare investment. He has served as a Board Director, Audit Committee Chair, Remuneration Committee member, and strategic advisor, with governance and operating experience spanning the United States, Europe, China, India, Africa and the Middle East. His expertise includes growth strategy, transformation, governance, investor engagement, and scaling businesses globally.

"We are delighted to welcome Martin to the NovaBridge Board," said Fu Wei, Chairman of the Board of NovaBridge. "Martin brings a rare combination of global healthcare experience, strategic insight, and governance expertise gained over decades of working with leading healthcare organizations around the world. As NovaBridge continues to grow and evolve, his perspective on board oversight, organizational development, and long-term value creation will be a valuable addition to our Board.”

“I am honored to join NovaBridge at this important stage. I look forward to supporting the Board and management team with an independent perspective on strategy, governance, and long-term value creation,” said Mr. Dewhurst.

The appointment follows the departure of independent director Liu Xin from the Board. The Company thanks Ms. Liu for her dedicated service and valuable contributions to NovaBridge.

About Martin Dewhurst

Martin Dewhurst has over 30 years of experience across biotech, biopharma, medical devices, health tech, and healthcare investment. Previously, he spent more than three decades at McKinsey & Company, where he co-led McKinsey’s Global Life Sciences Practice for seven years, doubling its scale and impact while innovating client services in digital and analytics. He also co-founded and co-led the McKinsey Health Institute, and led McKinsey’s Organization Practice in EMEA, with a focus on human capital, transformation, and post-merger integration. Earlier in his career, he worked with Arthur Andersen & Co. and BP Solar International.

Mr. Dewhurst currently serves on the boards of Swixx BioPharma AG, Turn Therapeutics Inc. (Nasdaq: TTRX), Unilabs SA, Cytovation ASA, and Distalmotion SA, where he chairs the Audit Committee. He is also a member of the Remuneration Committee at Cytovation ASA. Previously, he served as Chair of the Advisory Board of MedGenome Labs Ltd. Mr. Dewhurst also serves as a Senior Advisor to Revival Healthcare Capital, PJT Partners’ Life Sciences practice, and Lightrock.

Mr. Dewhurst received an M.B.A. from INSEAD, where he was named to the Dean’s List, and a B.A. from Magdalen College, Oxford.

About NovaBridge

NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing, and partnering strategy best suited to each program.

NovaBridge’s portfolio is led by givastomig and VIS-101. The Company's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing novel therapies to patients through the path best suited to each opportunity.

For more information, please visit www.novabridge.com and follow us on LinkedIn.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “believes,” “designed to,” “anticipates,” “future,” “intends,” “plans,” “potential,” “estimates,” “confident,” and similar terms or the negative thereof. NovaBridge may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expectations regarding the expected impact of the appointment of Mr. Dewhurst; the clinical development of the Company's drug candidates; and value creation. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application approval or eligibility for accelerated approval pathway or receipt of accelerated approval; the content and timing of decisions made by the relevant regulatory authorities, including the FDA, regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; the impact of macroeconomic conditions, including inflation, tariffs, volatile interest rates, regulatory uncertainty, potential government shutdowns, volatility in the capital markets, and regional and other global events, including ongoing armed conflicts in different regions of the world; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 7, 2026, and amended on June 16, 2026, as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

NovaBridge Investor & Media Contacts

NovaBridge Biosciences

+1-240-745-6330

IR@novabridge.com

Bill Begien, VP, Investor Relations

bill.begien@novabridge.com

Jessica Zhang, Director, Public Relations

jessica.zhang@novabridge.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 19.5 KB